5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 416-420

  Salepci, Taflan ^a   Seker, Mesut ^a   Uyarel, Huseyin ^b   Gumus, Mahmut ^a   Bilici, Ahmet ^a   Ustaalioğlu, Bala Basak Oven ^a   Öztürk, Akin ^a   Sonmez, Berkant ^a   Orcun, Asuman ^a   Ozates, Mustafa ^a   Irmak, Rahmi ^a   Yaylaci, Mustafa ^a  

^a DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

5 Fluorouracil; Angiotensin II; Cardiotoxicity; Vasoconstriction

Indexed keywords

ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; TROPONIN T;

ADULT; AGED; ANGIOTENSIN BLOOD LEVEL; ARTERY CONSTRICTION; ARTERY DIAMETER; ARTICLE; BLOOD CELL COUNT; BOLUS INJECTION; BRACHIAL ARTERY; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM; FEMALE; HUMAN; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; STATISTICAL ANALYSIS; VASOCONSTRICTION;

EID: 77953883562     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9226-8     Document Type: Article

References (16)

1. Haskell CM. Drugs used in cancer chemotherapy. In: Haskell CM, editor. Cancer treatment. Philadelphia, PA: Saunders; 1985. p. 70.
2. Roth A, Kolari C, Popovic S. Cardiotoxicity of 5-FU. Cancer Chemother Rep. 1975;59:1051-2.
3. Robben NC, Pippas AW, Moore JO, et al. The syndrome of 5- Fluorouracil cardiotoxicity. Cancer. 1992;71:493-509. doi:10.1002/ 1097-0142(19930115)71: 2<493::AID-CNCR2820710235>3.0. CO;2-C.
4. Becker K, Erckenbrecht JF, Häussinger D, et al. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs. 1999;57(4): 475-84. doi:10.2165/00003495-199957040-00003. (Pubitemid 29196916)
5. Freeman N, Costanza M. 5-Fluorouracil-associated cardiotoxicity. Cancer. 1998;61:36-45. doi:10.1002/1097-0142(19880101) 61:1<36::AID- CNCR2820610108>3.0.CO;2-6.
6. Porta C, Moroni M, Ferrari S, et al. Endotelin-1 and 5-Fluorouracil cardiotoxicity. Neoplasma. 1998;45:81-2.
7. Südhoff T, Enderle MD, Pahlke M, et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol. 2004;15:661-4. doi:10.10 93/annonc/mdh150.
8. Gamucci T, Zampa G. Cardiotoxicity of 5-Fluorouracil. Tumori. 1980;66:635-6.
9. Davidson JA. Prevention of 5-Fluorouracil associated cardiotoxicity. Aust NZ J Med. 1994;24:321.
10. Oleksowicz L, Bruckner HW. Prophylaxis of 5-Fluorouracilinduced coronary vasospasm with calcium channel blockers. Am J Med. 1988;85:750-1.
11. Burger AJ, Mannino S. 5-Fluorouracil-induced coronary vasospasm. Am Heart J. 1987;114:433-6. doi:10.1016/0002-8703(87) 90517-5.
12. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134(1):75-82. doi:10.1007/s00432-007-0250-9. (Pubitemid 350060687)
13. Frickhofen N, Beck FJ, Jung B, et al. Capecitabine can induce acute coronary syndrome similar to 5-Fluorouracil. Ann Oncol. 2002;13:797-801. doi:10.1093/annonc/mdf035. (Pubitemid 34567389)
14. Jensen SA, Sørensen JB. Risk factors and prevention of cardiotoxicity induced by 5-Fluorouracil or capecitabine. Cancer Chemother Pharmacol. 2006;58(4):487-93. doi:10.1007/s00280-005- 0178-1. (Pubitemid 43999797)
15. Patel B, Kloner RA, Ensley J, et al. 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci. 1987;294:238-43. doi:10.1097/00000441-1987 10000-00004.
16. Eskilsson J, Albertsson M. Failure of preventing 5-Fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol. 1990;8:1001-3. doi:10.3109/02841869009091790.